Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988188 | 1.00 | G6PD (0.58) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL3122440 | 0.90 | G6PD (0.72) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL11103160 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL27876896 | 0.88 | G6PD (0.57) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL3046110 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL19156397 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL6830022 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL3669161 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL16213874 | 0.88 | G6PD (0.71) | G6PDKMT2AAKR1B10AKR1B1MEN1 | |
| SCHEMBL9623230 | 0.87 | G6PD (0.56) | G6PDKMT2AAKR1B10AKR1B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513509-A4 | NEBULIZER FORMULATIONS OF DEHYDROEPIANDROSTERONE AND METHODS OF TREATING ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING COMPOSTIONS THEREOF | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7405207-B2 | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2007055890-A2 | CO-ADMINISTRATION OF DEHYDROEPIANDROSTERONE (DHEA) CONGENERS AND OTHER ACTIVE AGENTS FOR TREATING CANCER | INFLABLOC PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1033989-A4 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | DOWELL TAD (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | INFLABLOC PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | INFLABLOC PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006007312-A2 | CO-ADMINISTRATION OF DEHYDROEPIANDROSTERONE (DHEA) CONGENER WITH PHARMACEUTICALLY ACTIVE AGENTS FOR TREATING INFLAMMATION | INFLABLOC PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1589975-A2 | DEHYDROEPIANDROSTERONE (DHEA) CONGENERS FOR PREVENTION AND/OR TREATMENT OF ULCERS | Inflabloc Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-5977095-A | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999052532-A1 | METHOD FOR REDUCING CENTRAL NERVOUS SYSTEM IMPAIRMENT | PHARMADIGM, INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5922701-A | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999024039-A1 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | PHARMADIGM, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0915702-A2 | USE OF A DEHYDROEPIANDROSTERONE DERIVATIVE FOR ENHANCING OR ACCELERATING RE-EPITHELIALIZATION OR RE-ENDOTHELIALIZATION OF A TISSUE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5859000-A | ADMINISTERING DEHYDROEPIANDROSTERONE DERIVATIVE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998055074-A2 | METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998005338-A2 | USE OF A DEHYDROEPIANDROSTERONE DERIVATIVE FOR ENHANCING OR ACCELERATING RE-EPITHELIALIZATION OR RE-ENDOTHELIALIZATION OF A TISSUE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5175154-A | Antiobesity, antidiabetic, antilipemic, anticholesterol agents | RESEARCH CORPORATION TECHNOLOGIES, INC. | 1992-12-29 | — | — | US | disclosed |
| US-3758524-A | PROCESS FOR THE MANUFACTURE OF 21-FLUOROSTEROIDS | CIBA GEIGY CORP | 1973-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | CYP17A1, CYP21A2, SHBG | G6PD 163/4885KMT2A 3902/4885AKR1B10 52/4885 |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | CYP17A1, CYP21A2, HSD17B7 | G6PD 233/4885KMT2A 4046/4885AKR1B10 107/4885 |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | SHBG, CYP21A2, HSD17B11 | G6PD 129/4885KMT2A 3318/4885AKR1B10 86/4885 |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | SHBG, HSD17B11, HSD17B2 | G6PD 211/4885KMT2A 3325/4885AKR1B10 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.